PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Lupus Science & Medicine2 citationsOpen Access

Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

PVPaola Vidal-MontalAFAina FabregatIAIrene Altabás-González

Key Points

  • High renal response rates were observed with belimumab-based triple therapy, indicating its effectiveness.
  • Extrarenal response rates also showed substantial improvement, emphasizing comprehensive treatment benefits.
  • Data analysis from the BEL-SPAIN Registry highlights real-world efficacy and safety in clinical practice.
  • Effects demonstrate potential for increased GC-sparing outcomes and treat-to-target strategies in therapy.

Abstract

BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vidal-Montal et al. (2026) studied this question.

synapsesocial.com/papers/69a75b7fc6e9836116a22ed1https://doi.org/10.1136/lupus-2025-001825
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices2018 · 1,054 citations
  2. 2Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting2020 · 118 citations
  3. 3The frequency and outcome of lupus nephritis: results from an international inception cohort study2015 · 648 citations
  4. 4Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria2011 · 25 citations
  5. 5Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide2010 · 91 citations